Premium
Anti‐myelin‐associated glycoprotein antibody in sera from patients with demyelinating diseases
Author(s) -
Sato S.,
Baba H.,
Inuzuka T.,
Miyatake T.
Publication year - 1986
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1986.tb04636.x
Subject(s) - immunology , medicine , subacute sclerosing panencephalitis , antibody , multiple sclerosis , chronic inflammatory demyelinating polyneuropathy , guillain barre syndrome , polyneuropathy , myelin associated glycoprotein , myelin , pathology , central nervous system , measles virus , measles , vaccination
An enzyme‐linked immunosorbent assay (ELISA) was developed for quantitating anti‐myelin‐associated glycoprotein (MAG) IgM antibody in human sera. Absorbance values of anti‐MAG antibody were higher than 0.2 at 1:80 of serum dilution in sera from some patients with demyelinating diseases of the central or peripheral nervous systems including multiple sclerosis, subacute sclerosing panencephalitis, Guillain‐Barré syndrome, chronic relapsing polyradiculoneuritis and carcinomatous polyneuropathy and also some patients with autoimmune diseases such as collagen diseases and myasthenia gravis. However, absorbance values of anti‐MAG antibody in sera from control individuals and patients with some other neurological diseases were less than 0.2 and considered as negative. Because of the reported existence of a cross antigenicity between MAG and lymphocyte, and especially natural killer cells, the possibility of the functional importance of anti‐MAG antibody on cellular immunity is discussed with particular reference to the demyelinating diseases.